Autoimmune Disease Diagnostics Market (Test Type - Antinuclear Antibody Tests, Autoantibody Tests, Complete Blood Count (CBC), Comprehensive Metabolic Panel, C-reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), and Urinalysis; Disease Type - Graves’ Disease, Hashimoto’s Thyroiditis, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (Lupus), and Type 1 Diabetes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

Description

The global autoimmune disease diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, high prevalence of autoimmune diseases across the world, Increased health care expenditure globally, Growing awareness among people about autoimmune diseases are projected to drive the global autoimmune disease diagnostics market during the forecast period

According to the report, the global autoimmune disease diagnostics market was valued at US$ 14.4 Bn in 2018 and is anticipated to expand at a CAGR of 3.8% from 2019 to 2027

High Prevalence of Autoimmune Diseases across the World and Increased Health Care Expenditure Globally: Key Drivers

Rise in the prevalence of autoimmune diseases directly affects the growth and development of the autoimmune disease diagnostics market. The market is estimated to grow at a high rate due to rising incidence of diseases such as systemic lupus erythematosus, rheumatoid arthritis, Hashimoto’s thyroiditis, Graves’ disease, and type 1 diabetes.

According to the National Institutes of Health, up to 23.5 million Americans (more than seven percent of the population) suffer from an autoimmune disease - and the prevalence is rising. The rising prevalence of autoimmune diseases is likely to fuel the growth of the autoimmune disease diagnostics market. Therefore, consistent increase in the autoimmune patient population across the world has been identified as one of the major factors driving the autoimmune disease diagnostics market.

Technological advancements in diagnostic techniques for autoimmune diseases have helped extend the life expectancy of people and led to increased cost of treatment. Governments across the world are increasing their spending to provide better health care services. For instance, an analysis based on preliminary government data by the Centers for Medicare & Medicaid Services revealed that health care spending in the U.S. increased by 5% in 2014 as compared to 3.6% in 2013. Apart from developed countries, health care spending is also rising in developing parts of the world such as India and China. These countries are focusing on providing better health care services to a large population base.

Growing Awareness among People about Autoimmune Diseases Boost Market Growth

Increasing awareness and knowledge about autoimmune diseases among patients and care-givers would significantly contribute to the growth of the autoimmune disease diagnostics market

AARDA initiated the formation of the Center for Autoimmune Disease Research at Johns Hopkins University Medical Center and the NIH established Centers of Excellence in autoimmune diseases. AARDA also sponsors various programs and workshops aimed at bringing together researchers from different disciplines involved in autoimmune research. These factors are likely to fuel the growth of the market.

Rising awareness among people and increasing government initiatives are the major factors driving the autoimmune disease diagnostics market

Competitive Pricing and Equipment Costs to Hamper Market

The autoimmune disease diagnostics market is characterized by intense competition from local manufacturers that offer products at low cost. This is expected to hamper market growth as competition could lead to fall in prices of the products.

Moreover, with continuous technological developments in the autoimmune disease diagnostics market with respect to accuracy and efficiency, manufacturers are expected to provide up-to-date solutions to the customers. Customers are in fact hesitant to opt for cost-intensive upgrade procedures as they need to invest more capital for technologically advanced procedures and products.

Therefore, intense competition among players leading to low cost of products and procedures would hamper the growth of the autoimmune disease diagnostics market during the forecast period from 2019 to 2027

Global Autoimmune Disease Diagnostics Market: Competitive Landscape

This report profiles major players in the global autoimmune disease diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global autoimmune disease diagnostics market is highly fragmented, with the presence of a number of international as well as regional players

Leading players operating in the global autoimmune disease diagnostics market are

  • Abbott Laboratories, Inc.,
  • Beckman Coulter, Inc. ,
  • bioMérieux SA,
  • Bio-Rad Laboratories,
  • F. Hoffmann-La, Roche Ltd.,
  • Inova Diagnostics, Inc.,
  • Quest Diagnostics,
  • SQI Diagnostics, Inc.,
  • Siemens Healthcare among others

Global Autoimmune Disease Diagnostics Market: Key Developments

Key players in the global autoimmune disease diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global autoimmune disease diagnostics market. A few expansion strategies adopted by players operating in the global autoimmune disease diagnostics market are:

In March 2019, Abbott received CE Mark for its Alinity m diagnostics system and assays. This new technology will help keep up with the growing demand for infectious disease testing.

In June 2016, Beckman Coulter Diagnostics announced that it is ramping up its commercial focus on the Indian subcontinent with a series of steps that will help substantially increase its customer base- small- to large-volume hospital pathology laboratories.

In February 2019, Roche have entered into a definitive merger agreement with Spark Therapeutics, Inc. at a price of US$ 114.50 per share in an all-cash transaction.

The report on the global autoimmune disease diagnostics market discussed individual strategies, followed by company profiles of manufacturers of autoimmune disease diagnostics. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global autoimmune disease diagnostics market.

Key Questions Answered in Global Autoimmune Disease Diagnostics Market Report

  • What is the scope of growth of product companies in the global autoimmune disease diagnostics market?
  • What will be the Y-o-Y growth of the global autoimmune disease diagnostics market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global autoimmune disease diagnostics market?
  • Will North America continue to be the most profitable market for autoimmune disease diagnostics devices providers?
  • Which factors are anticipated to hamper the growth of the global autoimmune disease diagnostics market during the forecast period?
  • Which are the leading companies in the global autoimmune disease diagnostics market?

Global Autoimmune Disease Diagnostics Market - Segmentation

Test Type

  • Antinuclear Antibody Test
  • Autoantibody Test
  • Complete Blood Count (CBC)
  • Comprehensive Metabolic Panel
  • C-reactive Protein (CRP) Test
  • Erythrocyte Sedimentation Rate (ESR)
  • Urinalysis
  • Others

Disease Type

  • Graves’ Disease
  • Hashimoto’s Thyroiditis
  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • SLE (Lupus)
  • Type 1 Diabetes
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Autoimmune Disease Diagnostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Test Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Autoimmune Disease Diagnostics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Technological Development

    5.2. Disease Prevalence & Incidence Cases

6. Global Autoimmune Disease Diagnostics Market Analysis and Forecast, by Test Type

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Autoimmune Disease Diagnostics Market Value Forecast, by Test Type, 2017–2027

        6.2.1. Antinuclear Antibody Test

        6.2.2. Autoantibody Test

        6.2.3. Complete Blood Count (CBC)

        6.2.4. Comprehensive Metabolic Panel

        6.2.5. C-reactive Protein (CRP) Test

        6.2.6. Erythrocyte Sedimentation Rate (ESR)

        6.2.7. Urinalysis

        6.2.8. Others

    6.3. Global Autoimmune Disease Diagnostics Market Attractiveness, by Test Type

7. Global Autoimmune Disease Diagnostics Market Analysis and Forecast, by Disease Type

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Autoimmune Disease Diagnostics Market Value Forecast, by Disease Type, 2017–2027

        7.2.1. Graves’ Disease

        7.2.2. Hashimoto’s Thyroiditis

        7.2.3. Multiple Sclerosis

        7.2.4. Rheumatoid Arthritis

        7.2.5. SLE (Lupus)

        7.2.6. Type 1 Diabetes

        7.2.7. Others

    7.3. Global Autoimmune Disease Diagnostics Market Attractiveness, by Disease Type

8. Global Autoimmune Disease Diagnostics Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Autoimmune Disease Diagnostics Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. North America Autoimmune Disease Diagnostics Market Attractiveness, by Region

9. North America Autoimmune Disease Diagnostics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        9.2.1. Antinuclear Antibody Test

        9.2.2. Autoantibody Test

        9.2.3. Complete Blood Count (CBC)

        9.2.4. Comprehensive Metabolic Panel

        9.2.5. C-reactive Protein (CRP) Test

        9.2.6. Erythrocyte Sedimentation Rate (ESR)

        9.2.7. Urinalysis

        9.2.8. Others

    9.3. North America Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

        9.3.1. Graves’ Disease

        9.3.2. Hashimoto’s Thyroiditis

        9.3.3. Multiple Sclerosis

        9.3.4. Rheumatoid Arthritis

        9.3.5. SLE (Lupus)

        9.3.6. Type 1 Diabetes

        9.3.7. Others

    9.4. North America Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Autoimmune Disease Diagnostics Market Attractiveness Analysis

        9.5.1. By Test Type

        9.5.2. By Disease Type

        9.5.3. By Country

10. Europe Autoimmune Disease Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        10.2.1. Antinuclear Antibody Test

        10.2.2. Autoantibody Test

        10.2.3. Complete Blood Count (CBC)

        10.2.4. Comprehensive Metabolic Panel

        10.2.5. C-reactive Protein (CRP) Test

        10.2.6. Erythrocyte Sedimentation Rate (ESR)

        10.2.7. Urinalysis

        10.2.8. Others

    10.3. Europe Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

        10.3.1. Graves’ Disease

        10.3.2. Hashimoto’s Thyroiditis

        10.3.3. Multiple Sclerosis

        10.3.4. Rheumatoid Arthritis

        10.3.5. SLE (Lupus)

        10.3.6. Type 1 Diabetes

        10.3.7. Others

    10.4. Europe Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Autoimmune Disease Diagnostics Market Attractiveness Analysis

        10.5.1. By Test Type

        10.5.2. By Disease Type

        10.5.3. By Country/Sub-region

11. Asia Pacific Autoimmune Disease Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        11.2.1. Antinuclear Antibody Test

        11.2.2. Autoantibody Test

        11.2.3. Complete Blood Count (CBC)

        11.2.4. Comprehensive Metabolic Panel

        11.2.5. C-reactive Protein (CRP) Test

        11.2.6. Erythrocyte Sedimentation Rate (ESR)

        11.2.7. Urinalysis

        11.2.8. Others

    11.3. Asia Pacific Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

        11.3.1. Graves’ Disease

        11.3.2. Hashimoto’s Thyroiditis

        11.3.3. Multiple Sclerosis

        11.3.4. Rheumatoid Arthritis

        11.3.5. SLE (Lupus)

        11.3.6. Type 1 Diabetes

        11.3.7. Others

    11.4. Asia Pacific Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Autoimmune Disease Diagnostics Market Attractiveness Analysis

        11.5.1. By Test Type

        11.5.2. By Disease Type

        11.5.3. By Country/Sub-region

12. Latin America Autoimmune Disease Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        12.2.1. Antinuclear Antibody Test

        12.2.2. Autoantibody Test

        12.2.3. Complete Blood Count (CBC)

        12.2.4. Comprehensive Metabolic Panel

        12.2.5. C-reactive Protein (CRP) Test

        12.2.6. Erythrocyte Sedimentation Rate (ESR)

        12.2.7. Urinalysis

        12.2.8. Others

    12.3. Latin America Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

        12.3.1. Graves’ Disease

        12.3.2. Hashimoto’s Thyroiditis

        12.3.3. Multiple Sclerosis

        12.3.4. Rheumatoid Arthritis

        12.3.5. SLE (Lupus)

        12.3.6. Type 1 Diabetes

        12.3.7. Others

    12.4. Latin America Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America Latin America

    12.5. Latin America Autoimmune Disease Diagnostics Market Attractiveness Analysis

        12.5.1. By Test Type

        12.5.2. By Disease Type

        12.5.3. By Country/Sub-region

13. Middle East & Africa Autoimmune Disease Diagnostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        13.2.1. Antinuclear Antibody Test

        13.2.2. Autoantibody Test

        13.2.3. Complete Blood Count (CBC)

        13.2.4. Comprehensive Metabolic Panel

        13.2.5. C-reactive Protein (CRP) Test

        13.2.6. Erythrocyte Sedimentation Rate (ESR)

        13.2.7. Urinalysis

        13.2.8. Others

    13.3. Middle East & Africa Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

        13.3.1. Graves’ Disease

        13.3.2. Hashimoto’s Thyroiditis

        13.3.3. Multiple Sclerosis

        13.3.4. Rheumatoid Arthritis

        13.3.5. SLE (Lupus)

        13.3.6. Type 1 Diabetes

        13.3.7. Others

    13.4. Middle East & Africa Autoimmune Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Autoimmune Disease Diagnostics Market Attractiveness Analysis

        13.5.1. By Test Type

        13.5.2. By Disease Type

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by Tier and Size of companies)

    14.2. Market Share / Position Analysis, by Company, 2018

    14.3. Competitive Business Strategies

    14.4. Company Profiles

        14.4.1. Abbott Laboratories, Inc.

            14.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.1.2. Financial Analysis

            14.4.1.3. Growth Strategies

            14.4.1.4. SWOT Analysis

        14.4.2. Beckman Coulter, Inc.

            14.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.2.2. Financial Analysis

            14.4.2.3. Growth Strategies

            14.4.2.4. SWOT Analysis

        14.4.3. bioMérieux SA  

            14.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.3.2. Financial Analysis

            14.4.3.3. Growth Strategies

            14.4.3.4. SWOT Analysis

        14.4.4. Bio-Rad Laboratories  

            14.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.4.2. Financial Analysis

            14.4.4.3. Growth Strategies

            14.4.4.4. SWOT Analysis

        14.4.5. F. Hoffmann-La Roche Ltd.

            14.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.5.2. Financial Analysis

            14.4.5.3. Growth Strategies

            14.4.5.4. SWOT Analysis

        14.4.6. Inova Diagnostics, Inc.

            14.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.6.2. Financial Analysis

            14.4.6.3. Growth Strategies

            14.4.6.4. SWOT Analysis

        14.4.7. Quest Diagnostics

            14.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.7.2. Financial Analysis

            14.4.7.3. Growth Strategies

            14.4.7.4. SWOT Analysis

        14.4.8. Siemens Healthcare

            14.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.8.2. Financial Analysis

            14.4.8.3. Growth Strategies

            14.4.8.4. SWOT Analysis

        14.4.9. SQI Diagnostics, Inc.

            14.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.4.9.2. Growth Strategies

            14.4.9.3. SWOT Analysis

Choose License Type

Checkout Inquiry Sample